epo protein Search Results


recombinant rat erythropoietin rrepo  (R&D Systems)
90
R&D Systems recombinant rat erythropoietin rrepo
Recombinant Rat Erythropoietin Rrepo, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant rat erythropoietin rrepo/product/R&D Systems
Average 90 stars, based on 1 article reviews
recombinant rat erythropoietin rrepo - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
s19 compound pa463  (Chem Impex International)
95
Chem Impex International s19 compound pa463
S19 Compound Pa463, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s19 compound pa463/product/Chem Impex International
Average 95 stars, based on 1 article reviews
s19 compound pa463 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
recombinant mouse erythropoietin  (R&D Systems)
94
R&D Systems recombinant mouse erythropoietin
Recombinant Mouse Erythropoietin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse erythropoietin/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant mouse erythropoietin - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
epo protein  (R&D Systems)
93
R&D Systems epo protein
Epo Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/epo protein/product/R&D Systems
Average 93 stars, based on 1 article reviews
epo protein - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
epo 959 me r d systems  (R&D Systems)
93
R&D Systems epo 959 me r d systems
Epo 959 Me R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/epo 959 me r d systems/product/R&D Systems
Average 93 stars, based on 1 article reviews
epo 959 me r d systems - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
recombinant human soluble epo receptor  (R&D Systems)
94
R&D Systems recombinant human soluble epo receptor
Figure 1. Results of immunohistochemical studies. Contiguous tissue sections from breast tumors were immunostained to detect <t>EPO,</t> EpoR, or presence of pimonidazole adducts as a marker for hypoxia. Panels A, B, and C, Immunostaining of contiguous sections from the same tumor showing reactivity for EpoR (A), EPO (B), and pimonidazole adducts (C). Panels D and E, Immunostaining of contiguous sections for EpoR (D) and EPO (E), demonstrating EpoR immunoreactivity and no EPO expression. Panel F, High magnification of tissue section showing strong EpoR immunoreactivity in breast cancer cells. Panel G, Z-chamber consists of plexiglass rings (1), with an access port on the side (2), and covered with 180 m nylon mesh on both sides allowing the in-growth of vessels (3). Panels H and I, Representative section of tumor removed from Z-chamber stained with hematoxylin and eosin (H & E). Panel H, Histology of typical tumor formation at Day 7 after implantation of the T-ZCs. The maximal tumor depth (green arrow) is representative of negative control chambers containing rat mammary adenocarcinoma R3230 Ac cells and vehicle. Panel I, Reduction in maximal tumor depth (green arrow) observed in a T-ZC containing <t>recombinant</t> soluble EpoR (compare panels H and I). A to F, bar indicates 100 m; H and I, bar indicates 500 m.
Recombinant Human Soluble Epo Receptor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human soluble epo receptor/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant human soluble epo receptor - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
rat recombinant r epo  (R&D Systems)
93
R&D Systems rat recombinant r epo
Figure 1. Results of immunohistochemical studies. Contiguous tissue sections from breast tumors were immunostained to detect <t>EPO,</t> EpoR, or presence of pimonidazole adducts as a marker for hypoxia. Panels A, B, and C, Immunostaining of contiguous sections from the same tumor showing reactivity for EpoR (A), EPO (B), and pimonidazole adducts (C). Panels D and E, Immunostaining of contiguous sections for EpoR (D) and EPO (E), demonstrating EpoR immunoreactivity and no EPO expression. Panel F, High magnification of tissue section showing strong EpoR immunoreactivity in breast cancer cells. Panel G, Z-chamber consists of plexiglass rings (1), with an access port on the side (2), and covered with 180 m nylon mesh on both sides allowing the in-growth of vessels (3). Panels H and I, Representative section of tumor removed from Z-chamber stained with hematoxylin and eosin (H & E). Panel H, Histology of typical tumor formation at Day 7 after implantation of the T-ZCs. The maximal tumor depth (green arrow) is representative of negative control chambers containing rat mammary adenocarcinoma R3230 Ac cells and vehicle. Panel I, Reduction in maximal tumor depth (green arrow) observed in a T-ZC containing <t>recombinant</t> soluble EpoR (compare panels H and I). A to F, bar indicates 100 m; H and I, bar indicates 500 m.
Rat Recombinant R Epo, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat recombinant r epo/product/R&D Systems
Average 93 stars, based on 1 article reviews
rat recombinant r epo - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
recombinant vegf protein  (Sino Biological)
94
Sino Biological recombinant vegf protein
Figure 1. Results of immunohistochemical studies. Contiguous tissue sections from breast tumors were immunostained to detect <t>EPO,</t> EpoR, or presence of pimonidazole adducts as a marker for hypoxia. Panels A, B, and C, Immunostaining of contiguous sections from the same tumor showing reactivity for EpoR (A), EPO (B), and pimonidazole adducts (C). Panels D and E, Immunostaining of contiguous sections for EpoR (D) and EPO (E), demonstrating EpoR immunoreactivity and no EPO expression. Panel F, High magnification of tissue section showing strong EpoR immunoreactivity in breast cancer cells. Panel G, Z-chamber consists of plexiglass rings (1), with an access port on the side (2), and covered with 180 m nylon mesh on both sides allowing the in-growth of vessels (3). Panels H and I, Representative section of tumor removed from Z-chamber stained with hematoxylin and eosin (H & E). Panel H, Histology of typical tumor formation at Day 7 after implantation of the T-ZCs. The maximal tumor depth (green arrow) is representative of negative control chambers containing rat mammary adenocarcinoma R3230 Ac cells and vehicle. Panel I, Reduction in maximal tumor depth (green arrow) observed in a T-ZC containing <t>recombinant</t> soluble EpoR (compare panels H and I). A to F, bar indicates 100 m; H and I, bar indicates 500 m.
Recombinant Vegf Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant vegf protein/product/Sino Biological
Average 94 stars, based on 1 article reviews
recombinant vegf protein - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
recombinant canine epo  (Bio-Techne corporation)
94
Bio-Techne corporation recombinant canine epo
Figure 1. Results of immunohistochemical studies. Contiguous tissue sections from breast tumors were immunostained to detect <t>EPO,</t> EpoR, or presence of pimonidazole adducts as a marker for hypoxia. Panels A, B, and C, Immunostaining of contiguous sections from the same tumor showing reactivity for EpoR (A), EPO (B), and pimonidazole adducts (C). Panels D and E, Immunostaining of contiguous sections for EpoR (D) and EPO (E), demonstrating EpoR immunoreactivity and no EPO expression. Panel F, High magnification of tissue section showing strong EpoR immunoreactivity in breast cancer cells. Panel G, Z-chamber consists of plexiglass rings (1), with an access port on the side (2), and covered with 180 m nylon mesh on both sides allowing the in-growth of vessels (3). Panels H and I, Representative section of tumor removed from Z-chamber stained with hematoxylin and eosin (H & E). Panel H, Histology of typical tumor formation at Day 7 after implantation of the T-ZCs. The maximal tumor depth (green arrow) is representative of negative control chambers containing rat mammary adenocarcinoma R3230 Ac cells and vehicle. Panel I, Reduction in maximal tumor depth (green arrow) observed in a T-ZC containing <t>recombinant</t> soluble EpoR (compare panels H and I). A to F, bar indicates 100 m; H and I, bar indicates 500 m.
Recombinant Canine Epo, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant canine epo/product/Bio-Techne corporation
Average 94 stars, based on 1 article reviews
recombinant canine epo - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
recombinant mouse epor  (Sino Biological)
90
Sino Biological recombinant mouse epor
Figure 1. Results of immunohistochemical studies. Contiguous tissue sections from breast tumors were immunostained to detect <t>EPO,</t> EpoR, or presence of pimonidazole adducts as a marker for hypoxia. Panels A, B, and C, Immunostaining of contiguous sections from the same tumor showing reactivity for EpoR (A), EPO (B), and pimonidazole adducts (C). Panels D and E, Immunostaining of contiguous sections for EpoR (D) and EPO (E), demonstrating EpoR immunoreactivity and no EPO expression. Panel F, High magnification of tissue section showing strong EpoR immunoreactivity in breast cancer cells. Panel G, Z-chamber consists of plexiglass rings (1), with an access port on the side (2), and covered with 180 m nylon mesh on both sides allowing the in-growth of vessels (3). Panels H and I, Representative section of tumor removed from Z-chamber stained with hematoxylin and eosin (H & E). Panel H, Histology of typical tumor formation at Day 7 after implantation of the T-ZCs. The maximal tumor depth (green arrow) is representative of negative control chambers containing rat mammary adenocarcinoma R3230 Ac cells and vehicle. Panel I, Reduction in maximal tumor depth (green arrow) observed in a T-ZC containing <t>recombinant</t> soluble EpoR (compare panels H and I). A to F, bar indicates 100 m; H and I, bar indicates 500 m.
Recombinant Mouse Epor, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse epor/product/Sino Biological
Average 90 stars, based on 1 article reviews
recombinant mouse epor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
recombinant protein timp 1  (ProSci Incorporated)
94
ProSci Incorporated recombinant protein timp 1
Figure 1. Results of immunohistochemical studies. Contiguous tissue sections from breast tumors were immunostained to detect <t>EPO,</t> EpoR, or presence of pimonidazole adducts as a marker for hypoxia. Panels A, B, and C, Immunostaining of contiguous sections from the same tumor showing reactivity for EpoR (A), EPO (B), and pimonidazole adducts (C). Panels D and E, Immunostaining of contiguous sections for EpoR (D) and EPO (E), demonstrating EpoR immunoreactivity and no EPO expression. Panel F, High magnification of tissue section showing strong EpoR immunoreactivity in breast cancer cells. Panel G, Z-chamber consists of plexiglass rings (1), with an access port on the side (2), and covered with 180 m nylon mesh on both sides allowing the in-growth of vessels (3). Panels H and I, Representative section of tumor removed from Z-chamber stained with hematoxylin and eosin (H & E). Panel H, Histology of typical tumor formation at Day 7 after implantation of the T-ZCs. The maximal tumor depth (green arrow) is representative of negative control chambers containing rat mammary adenocarcinoma R3230 Ac cells and vehicle. Panel I, Reduction in maximal tumor depth (green arrow) observed in a T-ZC containing <t>recombinant</t> soluble EpoR (compare panels H and I). A to F, bar indicates 100 m; H and I, bar indicates 500 m.
Recombinant Protein Timp 1, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant protein timp 1/product/ProSci Incorporated
Average 94 stars, based on 1 article reviews
recombinant protein timp 1 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
his epor  (Sino Biological)
94
Sino Biological his epor
Figure 1. Results of immunohistochemical studies. Contiguous tissue sections from breast tumors were immunostained to detect <t>EPO,</t> EpoR, or presence of pimonidazole adducts as a marker for hypoxia. Panels A, B, and C, Immunostaining of contiguous sections from the same tumor showing reactivity for EpoR (A), EPO (B), and pimonidazole adducts (C). Panels D and E, Immunostaining of contiguous sections for EpoR (D) and EPO (E), demonstrating EpoR immunoreactivity and no EPO expression. Panel F, High magnification of tissue section showing strong EpoR immunoreactivity in breast cancer cells. Panel G, Z-chamber consists of plexiglass rings (1), with an access port on the side (2), and covered with 180 m nylon mesh on both sides allowing the in-growth of vessels (3). Panels H and I, Representative section of tumor removed from Z-chamber stained with hematoxylin and eosin (H & E). Panel H, Histology of typical tumor formation at Day 7 after implantation of the T-ZCs. The maximal tumor depth (green arrow) is representative of negative control chambers containing rat mammary adenocarcinoma R3230 Ac cells and vehicle. Panel I, Reduction in maximal tumor depth (green arrow) observed in a T-ZC containing <t>recombinant</t> soluble EpoR (compare panels H and I). A to F, bar indicates 100 m; H and I, bar indicates 500 m.
His Epor, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/his epor/product/Sino Biological
Average 94 stars, based on 1 article reviews
his epor - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


Figure 1. Results of immunohistochemical studies. Contiguous tissue sections from breast tumors were immunostained to detect EPO, EpoR, or presence of pimonidazole adducts as a marker for hypoxia. Panels A, B, and C, Immunostaining of contiguous sections from the same tumor showing reactivity for EpoR (A), EPO (B), and pimonidazole adducts (C). Panels D and E, Immunostaining of contiguous sections for EpoR (D) and EPO (E), demonstrating EpoR immunoreactivity and no EPO expression. Panel F, High magnification of tissue section showing strong EpoR immunoreactivity in breast cancer cells. Panel G, Z-chamber consists of plexiglass rings (1), with an access port on the side (2), and covered with 180 m nylon mesh on both sides allowing the in-growth of vessels (3). Panels H and I, Representative section of tumor removed from Z-chamber stained with hematoxylin and eosin (H & E). Panel H, Histology of typical tumor formation at Day 7 after implantation of the T-ZCs. The maximal tumor depth (green arrow) is representative of negative control chambers containing rat mammary adenocarcinoma R3230 Ac cells and vehicle. Panel I, Reduction in maximal tumor depth (green arrow) observed in a T-ZC containing recombinant soluble EpoR (compare panels H and I). A to F, bar indicates 100 m; H and I, bar indicates 500 m.

Journal: Laboratory investigation; a journal of technical methods and pathology

Article Title: Functional significance of erythropoietin receptor expression in breast cancer.

doi: 10.1097/01.lab.0000020415.72863.40

Figure Lengend Snippet: Figure 1. Results of immunohistochemical studies. Contiguous tissue sections from breast tumors were immunostained to detect EPO, EpoR, or presence of pimonidazole adducts as a marker for hypoxia. Panels A, B, and C, Immunostaining of contiguous sections from the same tumor showing reactivity for EpoR (A), EPO (B), and pimonidazole adducts (C). Panels D and E, Immunostaining of contiguous sections for EpoR (D) and EPO (E), demonstrating EpoR immunoreactivity and no EPO expression. Panel F, High magnification of tissue section showing strong EpoR immunoreactivity in breast cancer cells. Panel G, Z-chamber consists of plexiglass rings (1), with an access port on the side (2), and covered with 180 m nylon mesh on both sides allowing the in-growth of vessels (3). Panels H and I, Representative section of tumor removed from Z-chamber stained with hematoxylin and eosin (H & E). Panel H, Histology of typical tumor formation at Day 7 after implantation of the T-ZCs. The maximal tumor depth (green arrow) is representative of negative control chambers containing rat mammary adenocarcinoma R3230 Ac cells and vehicle. Panel I, Reduction in maximal tumor depth (green arrow) observed in a T-ZC containing recombinant soluble EpoR (compare panels H and I). A to F, bar indicates 100 m; H and I, bar indicates 500 m.

Article Snippet: In these experiments, recombinant human soluble EPO receptor (R and D Systems, Minneapolis, Minnesota) or neutralizing anti-EPO monoclonal antibody (MAB-287; R and D Systems) were reconstituted in PBS (cat#14190–144, Life Technologies) and added to the chambers at the indicated final concentrations.

Techniques: Immunohistochemical staining, Marker, Immunostaining, Expressing, Staining, Negative Control, Recombinant

Figure 3. Inhibition of tumor growth by EPO-EpoR antagonists. Rat R3230Ac mammary adenocarcinoma cells were injected into tumor Z-chambers as described in “Materials and Methods.” The chambers contained one-time doses each of recombinant sEpoR, MAB-287 anti-EPO neutralizing antibody, AG-490 Jak2 tyrosine kinase inhibitor, or vehicle (Control). Treatment groups are indicated on top of the chart and final concentrations of each compound are indicated on the x axis. At Day 7, the tumors in the Z-chambers were removed and H&E staining was performed. Quantitative analysis of maximal tumor depth was carried out in each treatment group and is expressed as a percentage of control, as indicated in the y axis. The data is expressed as mean standard error of the mean. To determine significant effects of treatment, the mean of each treatment group was compared with control using the Students t test (two-tail) and p values for each comparison are indicated above each bar. * p 0.05. NS, not significant.

Journal: Laboratory investigation; a journal of technical methods and pathology

Article Title: Functional significance of erythropoietin receptor expression in breast cancer.

doi: 10.1097/01.lab.0000020415.72863.40

Figure Lengend Snippet: Figure 3. Inhibition of tumor growth by EPO-EpoR antagonists. Rat R3230Ac mammary adenocarcinoma cells were injected into tumor Z-chambers as described in “Materials and Methods.” The chambers contained one-time doses each of recombinant sEpoR, MAB-287 anti-EPO neutralizing antibody, AG-490 Jak2 tyrosine kinase inhibitor, or vehicle (Control). Treatment groups are indicated on top of the chart and final concentrations of each compound are indicated on the x axis. At Day 7, the tumors in the Z-chambers were removed and H&E staining was performed. Quantitative analysis of maximal tumor depth was carried out in each treatment group and is expressed as a percentage of control, as indicated in the y axis. The data is expressed as mean standard error of the mean. To determine significant effects of treatment, the mean of each treatment group was compared with control using the Students t test (two-tail) and p values for each comparison are indicated above each bar. * p 0.05. NS, not significant.

Article Snippet: In these experiments, recombinant human soluble EPO receptor (R and D Systems, Minneapolis, Minnesota) or neutralizing anti-EPO monoclonal antibody (MAB-287; R and D Systems) were reconstituted in PBS (cat#14190–144, Life Technologies) and added to the chambers at the indicated final concentrations.

Techniques: Inhibition, Injection, Recombinant, Control, Staining, Comparison